Press Releases

Email Alerts

May 14, 2019

Biostage Reports First Quarter 2019 Financial Results

- Preparing to file first IND in Q3 2019

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
May 8, 2019

Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Tuesday May 14th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Mar 28, 2019

Biostage Reports 2018 Financial Results

- Pre-clinical and human compassionate use clinical evidence support IND filing mid-year 2019

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Mar 21, 2019

Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Thursday March 28th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Jan 28, 2019

First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting

Dennis Wigle, M.D., Ph.D, chair of thoracic surgery at Mayo Clinic in Rochester, Minnesota, speaking at the Society of Thoracic Surgeons Tech-Con 2019 meeting on January 26, announced for the...
Nov 8, 2018

Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Mr....
- Photos 1
Nov 8, 2018

Biostage Reports 2018 Third Quarter Financial Results

- Scientific feedback along with new and consistent data continue to validate technology

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Nov 7, 2018

Ms. Ting Li Appointed to Biostage Board of Directors

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus, and trachea, today announced...
- Photos 1
Nov 6, 2018

Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia

- These nondilutive funds support development, testing and IND submission of the Company's pediatric esophageal implant candidate

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
Nov 2, 2018

Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations

- Conference Call with Live Audio Webcast on Thursday November 8th at 9:30 AM ET -

Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...

Show per page